Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Fluicell AB's Enterprise Value is kr46.48 Mil.
Fluicell AB's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 was kr-6.49 Mil. Therefore, Fluicell AB's EV-to-FCF for today is -7.16.
The historical rank and industry rank for Fluicell AB's EV-to-FCF or its related term are showing as below:
OSTO:FLUI'
s EV-to-FCF Range Over the Past 10 Years
Min: -27.48 Med: -2.48 Max: 161.31
Current: -6.93
During the past 11 years, the highest EV-to-FCF of Fluicell AB was 161.31. The lowest was -27.48. And the median was -2.48.
OSTO:FLUI's EV-to-FCF is ranked worse than 100% of 314
companies
in the Biotechnology industry
Industry Median: 15.115
vs OSTO:FLUI: -6.93
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Fluicell AB's PE Ratio (TTM) for today is calculated as:
Fluicell AB's share price for today is kr32.40.
Fluicell AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr2.040.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Fluicell AB EV-to-FCF Related Terms
Fluicell AB EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Fluicell AB's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:FLUI vs VRTX, REGN, MRNA: EV-to-FCF Comparison
For the Biotechnology subindustry, Fluicell AB's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fluicell AB EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Fluicell AB's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Fluicell AB's EV-to-FCF falls into.
Fluicell AB's current Enterprise Value is kr46.48 Mil.
Fluicell AB's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-6.49 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fluicell AB (OSTO:FLUI) has a EV-to-FCF of -7.16 as of Sep. 10, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Fluicell AB and its competitors. According to the industry distribution chart, Fluicell AB ranks #999999 out of 314 companies in the Biotechnology industry.
Is Fluicell AB's EV-to-FCF too high?
Fluicell AB's current EV-to-FCF is -7.16. Based on the distribution chart, Fluicell AB ranks #999999 out of 314 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Fluicell AB has a GF Score™ of 45/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Fluicell AB's EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Fluicell AB ranks #999999 out of 314 companies for EV-to-FCF. This places Fluicell AB in the lower half of its industry. The industry median EV-to-FCF is 15.12. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 15.12, based on 314 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Fluicell AB and its competitors. For the Biotechnology industry, the median EV-to-FCF is 15.12 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fluicell AB's current EV-to-FCF is -7.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fluicell AB stock overvalued right now?
Based on GuruFocus' analysis, Fluicell AB (OSTO:FLUI) is currently considered Possible Value Trap. The stock's GF Value™ is kr80.39, compared to a current price of kr32.40 — trading 59.7% below its estimated fair value. The current EV-to-FCF is -7.16. Fluicell AB's overall GF Score™ is 45/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Fluicell AB (OSTO:FLUI), the current EV-to-FCF is -7.16 as of Sep. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fluicell AB (OSTO:FLUI) Overvalued in 2026?
Based on GuruFocus' analysis, Fluicell AB stock appears to be undervalued.
The current stock price of kr32.40 is trading 59.7% below its estimated GF Value™ of kr80.39.
GuruFocus considers Fluicell AB to be Possible Value Trap.
Key valuation signals for OSTO:FLUI:
EV-to-FCF: -7.16
GF Value™: kr80.39 vs. price of kr32.40 (59.7% below fair value)
No single metric tells the full story. See the OSTO:FLUI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fluicell AB is a Swedish life science company that conducts development in regenerative medicine and human tissue-based screening models for drug development, with a particular focus on the areas of type 1 diabetes, cardiac safety screening models, and kidney diseases. The company's platform for the production of human tissue that is based on Fluicell's technology for high-resolution 3D bioprinting, and which enables the creation of tissue-based products for use in drug development and regenerative medicine.
45GF Score
Get the complete analysis for OSTO:FLUI
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:FLUI has been successfully added to your 
